Search Results - will+flanagan

40 Results

Sort By:

Interactive Extended Reality Worlds with JSON Data Generated by Large Language Models

Recent LLM-XR systems mostly drive experiences by generating and compiling code on the fly. In complex scenes with thousands of artifacts and properties, models struggle to pick the right context, inflating token usage and still missing crucial constraints—like keeping cups on tables. Hallucinated or malformed scripts often fail to compile or...

Published: 10/10/2025 | Inventor(s): Tian Lan, Bin Li, Jiangong Chen

Keywords(s):

Category(s): Technology Classifications > Computers Electronics & Software > Artificial Intelligence, Technology Classifications > Computers Electronics & Software > Image Processing and Analysis

Tumor-pH–Triggered Doxorubicin Prodrug with On-Demand Shelf-Stable Precursor

This invention introduces a small-molecule doxorubicin prodrug that remains inert in blood and rapidly activates in the mildly acidic tumor microenvironment. Featuring a shelf-stable maleimide pre-prodrug that converts on demand to the ultra-acid-labile DMA form, it enables targeted chemotherapy with improved selectivity, scalable synthesis, and reduced...

Published: 10/10/2025 | Inventor(s): Ming An, Lan Yao, Vladyslav Nazarenko

Keywords(s): Technologies

Category(s): Campus > Binghamton University

Small molecule sAPPalpha enhancers that inhibit brain p-Tau as a therapeutic for Alzheimer’s Disease (UCLA Case No. 2025-163)

Contact UCLA Technology Development Group to learn more.

Published: 9/18/2025 | Inventor(s): Varghese John, Dongwook Wi, Jesus Campagna

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Discrete Approximation of Permanent Magnet Arrays (Case No. 2025-203)

Summary UCLA researchers have developed Discrete-MAG, a discrete magnetic actuation / magnetics platform that delivers precise, programmable magnetic field manipulation at small scales. The system aims to control magnetic particles or micro-devices discretely for applications in sensing, actuation, imaging, or biological interfacing. Background Magnetic...

Published: 10/14/2025 | Inventor(s): Tyler Clites, He Kai Lim, Will Flanagan, Cameron Taylor

Keywords(s):

Category(s): Materials, Materials > Functional Materials, Medical Devices, Mechanical, Mechanical > Robotics, Platforms, Platforms > Drug Delivery, Medical Devices > Medical Imaging, Life Science Research Tools, Life Science Research Tools > Research Methods

Ampule-Based Synthesis of Sulfur-Porous Carbon Composites for Lithium-Sulfur Batteries

Background Lithium/sulfur (Li/S) batteries are garnering significant attention as a promising solution for next-generation electrochemical energy storage. Their potential to revolutionize the battery industry stems from several key advantages that address the limitations of current lithium-ion (Li-ion) technology. These advantages include an exceptionally...

Published: 10/30/2025 | Inventor(s): Yoon Hwa, David Wright, Yuhui An

Keywords(s): Chemicals, Energy storage, Engineering, Materials, Nanomaterials, Synthesis

Category(s): Energy & Power, Physical Science, Advanced Materials/Nanotechnology, Semiconductors, Materials & Processes

Beam-controlled Spectral-selective Architecture for a Radiative Cooler

This invention enhances radiative cooling of buildings by manipulating the divergent angle of thermal emission. By adjusting the direction at which heat is diverted away from buildings by this beam controlled design, the dependence of radiative cooling performance on the presence of surrounding architecture and environment can be minimized. US12352...

Published: 10/22/2025 | Inventor(s): Qiaoqiang Gan, Lyu Zhou, Zongfu Yu, Haomin Song

Keywords(s):

Category(s): Technology Classifications > Energy Conservation

High-Potency Biased β2-adrenergic Receptor Agonist for Treating Respiratory Diseases

Advantages Ultra-potent β2-adrenergic receptor agonist that stimulates cAMP production with sub-nanomolar potency (EC50 = 0.25nM) Biased signaling profile selectively activates Gαs-mediated cAMP signaling while avoiding β-arrestin2 recruitment, reducing receptor desensitization characteristic of traditional treatments such as albuterol Maintains...

Published: 5/27/2025 | Inventor(s): Stephen Liggett, Donghwa Kim, Yu Chen, Jesper Madsen, Steven An

Keywords(s): Pharmaceuticals, Respiratory Diseases Treatment

Category(s): Technology Classifications > Medical > Respiratory, Technology Classifications > Medical > Therapeutics, Technology Classifications > Medical > Pharmaceuticals

S100A4 Monoclonal Antibody for Therapeutic and Diagnostic Use

Cancer metastasis are responsible for ~90% of cancer associated deaths. Recent studies suggest that immune cells play critical roles in promoting metastasis, especially myeloid cells from the bone marrow. UTHealth researchers, with researchers from Houston Methodist Hospital, observed a highly conserved expression of S100A4 in immune suppressive myeloid...

Published: 10/14/2025 | Inventor(s): Zhiqiang An, Ningyan Zhang

Keywords(s):

Category(s): Neurology/Neurosurgery, Oncology, Therapeutics

LILRB2 Monoclonal Antibody for Therapeutic and Diagnostic Uses of Neurodegenerative Diseases

Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays a key regulatory role in Alzheimer’s disease (AD) by controlling microglia activation and metabolic activities in brain tissues. TREM2 signaling inhibition is mediated by leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). UTHealth inventors created and engineered...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang

Keywords(s):

Category(s): Neurology/Neurosurgery, Therapeutics

Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer

Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered...

Published: 10/6/2025 | Inventor(s): Yves Pommier, Lin-kun An, Keli Agama, Evgeny Kiselev, Azhar Ravji

Keywords(s): Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

1 2 3 4